Essential thrombocythemia in patients with platelet counts below 600×109/L: Applicability of the 2008 World Health Organization diagnostic criteria revision proposal

American Journal of Hematology

Volumn 84, Issue 7, 2009, Pages 452-454

  Kwon, Mi ^a   Osorio, Santiago ^a   Muñoz, Carolina ^a   Sánchez, José Manuel ^a   Buno, Ismael ^a   Díez Martín, José Luis ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; GUIDELINES AS TOPIC; HUMANS; MIDDLE AGED; PLATELET COUNT; THROMBOCYTHEMIA, ESSENTIAL; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 67649703507     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21428     Document Type: Article

References (13)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood.. 2002;100:2292-2302.
2. Murphy S, Peterson P, Iland H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29-39. (Pubitemid 27063140)
3. Tefferi A, Hanson CA, Inwards DJ. How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc 2005;80: 923-936. (Pubitemid 40911466)
4. Sacchi S, Vinci G, Gugliotta L, et al. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600 3 10(9)/L. Gruppo Italiano Malattie Meloproliferative Croniche (GIMMC). Haematologica 2000;85:492-495.
5. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 3 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998;100:15-23.
6. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097. (Pubitemid 47281402)
7. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
8. Speletas M, Katodritou E, Daiou C, et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 2007;31:1053-1062. (Pubitemid 46873720)
9. Wolanskyj A, Lasho T, Schwager S, et al. JAK2V617F mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol 2005;131:208-213. (Pubitemid 43899687)
10. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: Pathogenesis, diagnosis, and management. Blood Rev 2001;15:121-131. (Pubitemid 32999197)
11. Lay M, Mariappan R, Gotlib J, et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn 2006;8: 330-334. (Pubitemid 44063809)
12. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes. Blood 2008;111:60-70.
13. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112:141-149.